October 21, 2023

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Key Points

Key points are not available for this paper at this time.

Abstract

The use of amivantamab-chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertions. (Funded by Janssen Research and Development; PAPILLON ClinicalTrials.gov number, NCT04538664.).

AI에게 질문

Bookmark

Cite This Study

Zhou et al. (Sat,) studied this question.

synapsesocial.com/papers/699ffdb1bae4b1758c863a8c https://doi.org/https://doi.org/10.1056/nejmoa2306441

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations2023 · 17 citations
2A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors2016 · 283 citations
3Current management of chemotherapy-induced neutropenia in adults: key points and new challenges2020 · 95 citations
4Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study.2022 · 3 citations
5Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets2022 · 36 citations

AI에게 질문

Bookmark